All In Biotech

Drug Trial Radar · NCT06212648

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

A Multi-center, Randomized, Double-blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 253 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

253

Actual

Start

Mar 25, 2022

Primary completion

Nov 27, 2022

Study completion Jan 27, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study purpose is to determine the appropriate combination drug dose by comparing safety and efficacy with placebo, candesartan, and amlodipine monotherapy after 8 weeks of administration of SPC1001 to patients with essential hypertension.

Conditions

  • Hypertension
  • Essential Hypertension

Interventions

  • SPC1001 HighDrug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

  • SPC1001 Mid1Drug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

  • SPC1001 Mid2Drug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

  • SPC1001 LowDrug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

  • SPC3001Drug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

  • SPC4001Drug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

  • SPC4002Drug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

  • PlaceboDrug

    Drugs for clinical trials are orally administered once a day after breakfast. After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MSSBP measures the amount of change after 8 weeks from baselineTime frame: 8 weeks from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHA Gangnam Medical Center, CHA University

    Seoul, Gangnam, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.